Get the Stockscreener App
369.11
0.82%
2.9068
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $369.11, with a volume of 965.35K.
It is up +0.82% in the last 24 hours and up +13.85% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$366.20
Open:
$362.655
24h Volume:
965.35K
Relative Volume:
0.34
Market Cap:
$198.92B
Revenue:
$36.71B
Net Income/Loss:
$7.71B
P/E Ratio:
25.94
EPS:
14.2284
Net Cash Flow:
$9.96B
1W Performance:
-3.93%
1M Performance:
+13.85%
6M Performance:
+27.61%
1Y Performance:
+24.33%
1-Day Range:
$361.71
$370.23
1-Week Range:
$361.00
$384.62
52-Week Range:
$261.43
$385.12
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
369.05 | 197.38B | 36.71B | 7.71B | 9.96B | 14.23 |
|
LLY
Lilly Eli Co
|
1,045.59 | 929.27B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
244.08 | 589.19B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
231.98 | 402.08B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
205.15 | 317.06B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
162.97 | 307.56B | 54.72B | 14.02B | 15.32B | 7.1855 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen wins new EU approval for Uplizna in gMG - European Pharmaceutical Review
Here's What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN) - Finviz
Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN) - Yahoo Finance
Amgen Inc. $AMGN Shares Sold by Savvy Advisors Inc. - MarketBeat
LSV Asset Management Raises Holdings in Amgen Inc. $AMGN - MarketBeat
Krilogy Financial LLC Takes $1.25 Million Position in Amgen Inc. $AMGN - MarketBeat
Baader Bank Aktiengesellschaft Lowers Position in Amgen Inc. $AMGN - MarketBeat
UPLIZNA’s Expanded EU Use in Autoimmune Disease Could Be A Game Changer For Amgen (AMGN) - simplywall.st
Amgen Conference: UPLIZNA Phase III Plans, Daxdilimab Lupus Data, and TEZSPIRE Expansion Update - Yahoo Finance
AMGN: Advancing late-stage trials and expanding TSLP-targeted therapies, with major data readouts ahead - TradingView
Traders Buy Large Volume of Amgen Call Options (NASDAQ:AMGN) - MarketBeat
Amgen wins EC approval for Uplizna in gMG - The Pharma Letter
Amgen wins EC approval for Uplinza in gMG - The Pharma Letter
Varma Mutual Pension Insurance Co Buys 7,300 Shares of Amgen Inc. $AMGN - MarketBeat
EUROPEAN COMMISSION APPROVES AMGEN'S UPLIZNA® FOR GENERALIZED MYASTHENIA GRAVIS - PR Newswire
Leuthold Group LLC Purchases New Stake in Amgen Inc. $AMGN - MarketBeat
Stratos Wealth Partners LTD. Has $8.83 Million Stake in Amgen Inc. $AMGN - MarketBeat
Cibc World Market Inc. Grows Stake in Amgen Inc. $AMGN - MarketBeat
ABC Arbitrage SA Cuts Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Ex-Dividend Reminder: Cencora, Amgen and Oppenheimer Holdings - Nasdaq
Amgen (NASDAQ:AMGN) Price Target Raised to $295.00 - MarketBeat
Rhumbline Advisers Sells 6,685 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52 - simplywall.st
Prospera Financial Services Inc Sells 6,723 Shares of Amgen Inc. $AMGN - MarketBeat
Caprock Group LLC Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Wealthfront Advisers LLC Grows Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Stock Holdings Reduced by Allegheny Financial Group - MarketBeat
How Amgen Inc. (AMGN) Affects Rotational Strategy Timing - Stock Traders Daily
AstraZeneca Unit Settles Soliris Feud With Samsung, Amgen - Law360
Mizuho Raises Price Target on Amgen to $295 From $280, Keeps Outperform Rating - marketscreener.com
Daiwa Securities Group Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
Just Two Days Till Amgen Inc. (NASDAQ:AMGN) Will Be Trading Ex-Dividend - 富途牛牛
United States Biotechnology Market to hit US$ 1.5 Trillion - openPR.com
Two Days Left Until Amgen Inc. (NASDAQ:AMGN) Trades Ex-Dividend - simplywall.st
Daiwa Securities Adjusts Price Target on Amgen to $410 From $370, Maintains Outperform Rating - marketscreener.com
The 5 Most Interesting Analyst Questions From Amgen's Q4 Earnings Call - Finviz
The 5 Most Interesting Analyst Questions From Amgen’s Q4 Earnings Call - The Globe and Mail
Alps Advisors Inc. Has $5.29 Million Stake in Amgen Inc. $AMGN - MarketBeat
Wesbanco Bank Inc. Increases Stake in Amgen Inc. $AMGN - MarketBeat
First National Trust Co Trims Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Amgen stands by vasculitis drug Tavneos after FDA wants it pulled - ANCA Vasculitis News
When Advocacy Meets Science in the Care of People Living with gMG - Amgen
Amgen, Merck share losses contribute to Dow's 200-point drop - MSN
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Yahoo Finance
Candriam S.C.A. Cuts Holdings in Amgen Inc. $AMGN - MarketBeat
ProShare Advisors LLC Sells 158,994 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen stock jumps to a 52-week high; here’s what to watch before Monday’s open - TechStock²
Kinsale Capital Group Inc. Has $9.65 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Bessemer Group Inc. Acquires 2,967 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Nov 20 '25 |
Sale |
337.26 |
3,139 |
1,058,667 |
7,225 |
3.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):